Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study ( er the past 2-3months and a decrease i...)

Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study

er the past 2-3 months and a decrease is therefore a measure of treatment effect. The higher the blood glucose the more glucose binds to haemoglobin (glycation).

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel (direct):
(+45) 4442 3450 Tel (direct):
(+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com

Katrine Sperling Hans Rommer
Tel (mobile):
(+45) 3079 6718 Tel (direct):
(+45) 4442 4765
krsp@novonordisk.com hrmm@novonordisk.com

In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel (direct):
(+1) 609 514 8316 Tel (direct):
(+1) 609 919 7937
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
2. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
3. Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients
4. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
5. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
6. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
7. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
8. 2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion

Post Your Comments:

(Date:11/29/2009)...wire/ -- A large proportion of patients who underg...e unindicated and unnecessary additional image acq...exposure, according to a study presented today at ...North America (RSNA). ,, "It is the responsibil...tion to ensure that the dosage is as low as reason...

(Date:11/29/2009)...Newswire/ -- Royal Philips Electronics ( PHG, AEX:...need by showing its portfolio of products designed...al meeting of the Radiological Society of North Am...ps are several advancements and upgrades focused o...streamlining workflow to expand upon clinical capa...

(Date:11/29/2009)...ewswire/ -- FUJIFILM Medical Systems USA, Inc., th...FFDM) with over 7,000 installations, is pleased to...me in the US. The Aspire HD combines the use of a...generation detector technology and the smallest pi... resolution at a reduced dose for the patient. Th...

Breaking Medicine Technology:Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients 2 Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients 3 Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 2 Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 3 Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 4 Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 5 FUJIFILM's DR-based FFDM System Makes US Debut at RSNA 2 FUJIFILM's DR-based FFDM System Makes US Debut at RSNA 3 FUJIFILM's DR-based FFDM System Makes US Debut at RSNA 4 Intralase 26amp 3B 238220 3BBladeless 26amp 3B 238221 3B Lasik Gains Popularity in the Raleigh NC Area 49584 1 Intralase 26amp 3B 238220 3BBladeless 26amp 3B 238221 3B Lasik Gains Popularity in the Raleigh NC Area 49584 2 U S Army Increases Medical and Dental School Benefits 49582 1 U S Army Increases Medical and Dental School Benefits 49582 2 U S Army Increases Medical and Dental School Benefits 49582 3 BioMed Realty Trust Closes New 2418 Million Secured Loan 49580 1 BioMed Realty Trust Closes New 2418 Million Secured Loan 49580 2 BioMed Realty Trust Closes New 2418 Million Secured Loan 49580 3

[0] Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients [0] Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients [0] FUJIFILM's DR-based FFDM System Makes US Debut at RSNA

...herapeutic Proteins at Tumor,Site, ARLINGTON HEIG...eons have delivered cancer fighting proteins throu...ith a 79 percent reduction,in tumor volume, accord...onstructive Surgery(R), the official medical journ...PS). This new delivery technique, which has,yet to...

...,AZN) today announced the submission of a suppleme...and Drug Administration (FDA) for SEROQUEL XR(TM),...seek approval for the,treatment of generalized anx...anxiety effect. It is the first time approval has ... in GAD. The submission is based on a robust,clini...

Other Medicine Technology:Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2 Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3 AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2 AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3 AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4 AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5 AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6 AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7 AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8

Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines

(Date:11/27/2009)...., Nov. 27 GSI Group Inc...of precision technology products and semiconductor...f the Company,s shareholders has been scheduled fo...f the meeting will be announced in due course. As...isition notice from Stephen Bershad, a holder of g...

(Date:11/27/2009)...Biotech firm Replikins Ltd. today issued its lates...ata. It shows that the lethality of the virus has...e virus,s current outbreak in the spring of 2009 t...d. 0.1). The H1N1 infectivity count, however, rema...PRWEB) November 27, 2009 -- Biotech firm Replikins...

(Date:11/27/2009)...Nov. 27 The Gymboree Cor...bert, CFO/COO, will present at the NASDAQ OMX 23rd...air Hotel in London, England, on Wednesday, Decemb...a live broadcast of The Gymboree Corporation,s pre...gymboree.com, click on "Our Company" at the bottom...

(Date:11/27/2009)...SEINE, France, Nov. 27 Team Garmin...ng team dedicated to ethical sporting and developi...nced today that it will become Team Garmin-Transit... new sponsor of the team. Transitions Optical is t...r, offering the most advanced photochromic technol...

(Date:11/27/2009)...XenaCare Holdings has announced that it has become...ne of the largest nonprofit organizations dedicate...n. , Delray Beach, FL (Vo...(OTCBB: XCHO), a company specializing in the marke...e products, has announced today that is has become...

Breaking Medicine News(10 mins):Health News:GSI Group Calls Shareholders Meeting 2 Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2 Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3 Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4 Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5 Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2 Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3 Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2 Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3 Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4

[0] GSI Group Calls Shareholders Meeting [0] Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased [0] The Gymboree Corporation to Present at NASDAQ OMX 23rd Investor Program [0] Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor [0] XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation

...nd New Regulations Could Hold the Key to ...ORK, Nov. 8 It is estimated that more than 1,mill...the United States in,2007. While most skin cancers...e hopeful that the recent introduction,of a new la...

...e the Effects of Stress on the Skin, Hair and ... 8 Pending job cuts at the office.,Back-to-back f.... What do,they all have in common? In a word -- st...acne, brittle nails or even hair,loss. Speaking t...

... Universities to Develop a New Thrombectomy ... ST. PAUL, Minn., Nov. 8 In a unanimous decision ... support of Governor John Hoeven,and the state,s C...tate University (NDSU) to develop and manufacture ...

...Diabetes Day, November 14,is observed every year b...,and by others with an interest in diabetes. This ...and adolescents," provides an excellent opportunit...lth (NIH), researchers at more,than 150 medical ce...

...umatic Brain Injuries: The Signature,Wounds of Ope...m, WASHINGTON, Nov. 8 - Veterans for America,s,"T...identifies a number of,interrelated trends adverse...l traumas., This report is the result of VFA,s ag...

...harma, Inc.,(Nasdaq: IDMI ) today announced its f...nded September 30, 2007. Financial information pre...Pharma and its subsidiary, IDM,S.A. Cash and cash...any,s net cash outflow from operations and,investm...

Skin Cancer Prevention Update:Feeling Stressed?North Dakota Grants Enova Medical Technologies a $2.5 Million Centers of Excellence Grant World Diabetes Day Spotlights Type 1 Diabetes Increase and World Class Response Trends in Treatment of America's Wounded Warriors IDM Pharma Reports Third Quarter 2007 Financial Results

...er is designed for fast & easy operation. The 5.7 ...for everyone., ,In AUTO mode, the readings are...ned. Multi-Focal lenses are automatically detected...rrectly position the lens. The color touch panel d...

Pro-lll

FF 450^plus Fundus Camera

TRC-50FXC

Medicine Products:

TL-3000B Auto Lensemeter Pro-lll FF 450^plus Fundus Camera TRC-50FXC

( er the past 2-3months and a decrease i...)Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study,Health